aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as
Company profile
Ticker
AIM
Exchange
Website
CEO
Thomas Equels
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
HEMISPHERX BIOPHARMA INC
SEC CIK
Corporate docs
Subsidiaries
BioPro Corp. • BioAegean Corp. • Aim ImmunoTech Europe ...
IRS number
520845822
AIM stock data
Latest filings (excl ownership)
424B5
Prospectus supplement for primary offering
31 May 24
10-Q
2024 Q1
Quarterly report
15 May 24
EFFECT
Notice of effectiveness
2 May 24
424B5
Prospectus supplement for primary offering
1 May 24
S-1
IPO registration
19 Apr 24
10-K
2023 FY
Annual report
29 Mar 24
D/A
$3.30 mm in debt, sold $3.30 mm, 1 investor
21 Feb 24
D
Exempt offering of security
20 Feb 24
8-K
Entry into a Material Definitive Agreement
20 Feb 24
8-K
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
9 Feb 24
Transcripts
AIM
Earnings call transcript
2024 Q1
16 May 24
AIM
Earnings call transcript
2023 Q4
2 Apr 24
AIM
Earnings call transcript
2023 Q3
15 Nov 23
AIM
Earnings call transcript
2023 Q2
15 Aug 23
AIM
Earnings call transcript
2023 Q2
15 Aug 23
AIM
Earnings call transcript
2023 Q1
16 May 23
AIM
Earnings call transcript
2022 Q4
3 Apr 23
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.30 mm | 3.30 mm | 3.30 mm | 3.30 mm | 3.30 mm | 3.30 mm |
Cash burn (monthly) | 714.67 k | 1.68 mm | 1.91 mm | 2.78 mm | 1.61 mm | 1.87 mm |
Cash used (since last report) | 1.47 mm | 3.45 mm | 3.93 mm | 5.72 mm | 3.30 mm | 3.84 mm |
Cash remaining | 1.82 mm | -153.16 k | -639.67 k | -2.43 mm | -9.05 k | -548.06 k |
Runway (months of cash) | 2.6 | -0.1 | -0.3 | -0.9 | -0.0 | -0.3 |
Institutional ownership, Q4 2023
0.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 6 |
Opened positions | 0 |
Closed positions | 32 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 40.21 mm |
Total shares | 91.39 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
SeaCrest Wealth Management | 37.06 k | $16.31 mm |
ForthRight Wealth Management | 20.00 k | $8.80 mm |
D.B. Root & Company | 12.05 k | $5.30 mm |
Traynor Capital Management | 11.78 k | $5.18 mm |
SNS Financial | 10.00 k | $4.40 mm |
AdvisorNet Financial | 500.00 | $220.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 May 24 | Equels Thomas K. | Common Stock | Buy | Acquire P | No | No | 0.405 | 61,729 | 25.00 k | 778,184 |
6 May 24 | Iii Peter W. Rodino | Common Stock | Buy | Acquire P | No | No | 0.405 | 30,865 | 12.50 k | 212,583 |
21 Mar 24 | Nancy Bryan | Common Stock | Buy | Acquire P | No | No | 0.39 | 38,462 | 15.00 k | 38,462 |
15 Mar 24 | Stewart Appelrouth | Common Stock | Buy | Acquire P | No | No | 0.33 | 90,910 | 30.00 k | 239,765 |
15 Mar 24 | Iii Peter W. Rodino | Common Stock | Buy | Acquire P | No | No | 0.33 | 37,879 | 12.50 k | 181,718 |
News
AIM ImmunoTech Completes cGMP Manufacturing Of Clinical Vials Of Ampligen
6 May 24
AIM ImmunoTech Q4 EPS $(0.26) Misses $(0.15) Estimate, Sales $65.00K Beat $40.00K Estimate
2 Apr 24
Earnings Scheduled For April 2, 2024
2 Apr 24
Preview: AIM ImmunoTech's Earnings
1 Apr 24
Earnings Scheduled For March 26, 2024
26 Mar 24
Press releases
AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering
31 May 24
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
20 May 24
AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update
16 May 24
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
9 May 24
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
6 May 24